89 - New Battles With Old Foes: Addressing Syphilis and Drug-Resistant Neisseria gonorrhea

Thursday, October 20, 2022

3:15 PM – 4:30 PM US ET

Location: 150 AB

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Moderator(s)

Anne-Catrin Uhlemann, MD, PhD

Associate Professor of Medicine
Columbia University Irving Medical Center
New York, NY, United States

Disclosure(s): Merck: Grant/Research Support (Ongoing)
Luiz Bermudez, MD

Professor
Oregon State University
Corvallis, OR, United States

Disclosure(s): No financial relationships to disclose

Faculty(s)

Justin Radolf, MD

Professor of Medicine/Director of Research, Department of Medicine
University of Connecticut Health
Avon, CT, United States

Disclosure(s): Biokit: licensing agreement for serodiagnostic reagents (Ongoing); Chembio: licensing agreement for serodiagnostic reagents (Ongoing)

Slides
Sanjay Ram, MBBS

Professor of Medicine
University of Massachusetts Chan Medical School
Worcester, MA, United States

Disclosure(s): Apellis Pharmaceuticals, Inc.: Advisor/Consultant (Terminated); Ionis Pharmaceuticals: Advisor/Consultant (Ongoing); STIRx, Inc: Ownership Interest (Ongoing)

Slides
Lindley Barbee, MD, MPH

Lead, Clinical Team
Centers for Disease Control and Prevention, DSTDP
Decatur, GA, United States

Disclosure(s): Hologic: Grant/Research Support (Ongoing); Nabriva Therapeutics US, Inc.,: Grant/Research Support (Ongoing); SpeedDx: Grant/Research Support (Ongoing)

Slides

Disclosure(s):

Anne-Catrin Uhlemann, MD, PhD: Merck: Grant/Research Support (Ongoing)

Luiz Bermudez, MD: No financial relationships to disclose

Justin D. Radolf, MD: Biokit: licensing agreement for serodiagnostic reagents (Ongoing); Chembio: licensing agreement for serodiagnostic reagents (Ongoing)

Sanjay Ram, MBBS: Apellis Pharmaceuticals, Inc.: Advisor/Consultant (Terminated); Ionis Pharmaceuticals: Advisor/Consultant (Ongoing); STIRx, Inc: Ownership Interest (Ongoing)

Lindley Barbee, MD, MPH: Hologic: Grant/Research Support (Ongoing); Nabriva Therapeutics US, Inc.,: Grant/Research Support (Ongoing); SpeedDx: Grant/Research Support (Ongoing)

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 contact hours of pharmacy CE
ACPE Number: JA0007082-0000-22-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

gain insights into the development of new approaches for prevention and treatment of syphilis based on the pathogenesis of the disease;
recognize the role of the complement system in Neisseria gonorrhea infections and its potential as a target for immunotherapy;
describe the increase in antibiotic resistance in Neisseria gonorrhea

Presentations:

3:15 PM – 3:40 PM US ET

The Treponema pallidum OMPeome: Roadmap for Syphilis Pathogenesis and Vaccine Development
Speaker: Justin D. Radolf, MD – University of Connecticut Health
3:40 PM – 4:05 PM US ET

Neisseria Gonorrhea, Tackling Complement to Develop Novel Immunotherapies
Speaker: Sanjay Ram, MBBS – University of Massachusetts Chan Medical School
4:05 PM – 4:30 PM US ET

Antimicrobial-Resistant N. Gonorrhoeae and Novel Alternative Treatment Approaches
Speaker: Lindley Barbee, MD, MPH – Centers for Disease Control and Prevention, DSTDP